13 September 2013
Macmillan urges the NHS to redesign cancer services
The cost of caring for inpatients with breast and prostate cancer in England will surge by a fifth (20%) in a decade, hitting at least £790million a year by 2020, according to new research by Macmillan Cancer Support1.
The Monitor Deloitte study - commissioned by Macmillan - revealed soaring inpatient costs for two of the most common types of cancer in England. This comes at a time when the number of people expected to get cancer in their lifetime is set to increase to almost one in two by 20202.
Inpatient costs for breast cancer in England are projected to rise by £87million between 2010 and 20203. For prostate cancer, the costs are predicted to increase by £44million4. Together these cancers account for almost a third (28%) of all new cases diagnosed each year in the UK5 and represent just part of the overall cost of inpatient care for cancer patients.
It is likely that the rise in costs is being driven mainly by the increasing numbers of people getting and surviving cancer, many of whom may need treatment for other health complications. Recent Macmillan research showed that one in four people living with cancer suffer poor health or disability caused by their illness6.
Professor Jane Maher, Chief Medical Officer at Macmillan Cancer Support, says:
'As the cost of caring for people with cancer in hospital escalates, it will be increasingly important that every patient receives a ‘cancer recovery package’ at the end of treatment. These are tailored to support people to manage their own recovery at home and prevent the chances of them having to go back to hospital because of other health problems linked to their cancer and its treatment.'
Ciarán Devane, Chief Executive at Macmillan Cancer Support, says:
'This research reveals just the tip of the iceberg of the total cost of treating the growing number of people living with cancer in the UK. It’s time for radical action.
'Macmillan’s work will become more vital than ever, but we cannot solve the problem alone. The way cancer services are delivered in the UK needs to be redesigned now by rolling out pilot programmes that have successfully coordinated health and social care and reduced the overall cost. This would deliver better care for people with cancer and would be cheaper for the NHS.'
No one should face cancer treatment alone. If you or someone you know needs information or support, please call 0808 808 00 00 or visit www.macmillan.org.uk.
For further information, please contact:
Claire Keuls, Senior Media & PR Officer, Macmillan Cancer Support
020 7840 4872 (out of hours 07801 307068)
Notes to Editors:
1 The cost comes from inpatient data only so excludes the large proportion of chemotherapy or radiotherapy delivered in an outpatient setting. It reflects the cost to the NHS budget, i.e. what commissioners pay hospitals to provide the care based on the NHS National Tariff, rather than the exact cost to hospitals of providing the care.
Routes from Diagnosis – breast, prostate, brain and lung framework. Macmillan Cancer support 2013.
2 Macmillan estimate based on; Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107: 1195-1202. (Scenario 1 presented here) Forman D, et al. Cancer prevalence in the UK: results from the EUROPREVAL Study. Annals of Oncology. 2003. 14: 648–654; Office for National Statistics; Information Services Division (ISD) Scotland; General Registrar Office Scotland; Welsh Cancer Intelligence & Surveillance Unit; Northern Ireland Cancer Registry; Northern Ireland Statistics and Research Agency
3 Inpatient costs in England projected to increase by £86.6m between 2010 and 2020 for breast cancer, from £387m in 2010 to £473.6m in 2020.
4 Inpatient costs in England projected to increase by £43.7m between 2010 and 2020 for prostate breast cancer, from £276.9m in 2010 to £320.6m in 2020.
5 There were over 330,000 new cases of cancer diagnosed in the UK in 2011, 28% were new cases of breast or prostate cancer. Data compiled from Office for National Statistics; Information Services Division (ISD) Scotland; Welsh Cancer Intelligence & Surveillance Unit; Northern Ireland Cancer Registry.
6 Macmillan estimate based on known cancer prevalence (Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107: 1195-1202) and expert consensus, see Macmillan Cancer Support (2013) Throwing light on the consequences of cancer and its treatment.
About Macmillan Cancer Support
More than one in three of us will get cancer. For most of us it will be the toughest fight we ever face. And the feelings of isolation and loneliness that so many people experience make it even harder.
But you don’t have to go through it alone. The Macmillan team is with you every step of the way.
We are the nurses and therapists helping you through treatment. The experts on the end of the phone. The advisers telling you which benefits you’re entitled to. The volunteers giving you a hand with the everyday things. The campaigners improving cancer care. The community there for you online, any time. The supporters who make it all possible.
Together, we are all Macmillan Cancer Support.